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Abstract: Bone marrow transplantation (BMT) was introduced as a treatment option 15 years 
ago for severe, drug-resistant multiple sclerosis (MS). Up until now, BMT has been undertaken 
in relatively few patients worldwide, with moderate success, and recent studies suggest that 
patients with early, highly aggressive MS benefit most from this treatment. In this work, we 
determined peripheral blood lymphocyte populations in a patient (patient A) with remitting–
relapsing multiple sclerosis (RR-MS), refractory to conventional treatments, and who underwent 
BMT, relapsed, and has been treated with natalizumab for the last 22 months. Eleven other 
RR-MS patients in the acute phase of the disease, untreated or treated with interferon-beta, 
and 20 healthy subjects served as controls. Natalizumab treatment in patient A resulted in lym-
phocytosis and increased levels of CD20+/CD20+CD5+ B cells and T regulatory cells (Tregs). 
The patient maintained relatively low levels of T cells, T helper cells, memory T helper cells, 
and naive cytotoxic T cells, and very low levels of naive T helper cells and natural killer cells 
throughout. The Tregs of patient A post-treatment with natalizumab responded well in culture to 
a peptide mapping to a myelin basic protein antigenic epitope (mean 42% increase) compared 
with Tregs of healthy controls (mean 15% increase) whereas Tregs of the RR-MS controls or 
patient A prenatalizumab treatment either did not respond or responded adversely to the peptide 
(mean 3% and 21% decreases, respectively). Since the beginning of natalizumab treatment, 
patient A has had no relapses, and his Expanded Disability Status Score has improved. From the 
parameters studied, Treg responsiveness to autoantigens seems to be an important differentiating 
factor in RR-MS progression.
Keywords: bone marrow transplantation, lymphocytes, multiple sclerosis, myelin basic protein 
antigen, peptide, phenotype, remitting–relapsing, T regulatory cells
Introduction
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous 
system. Derangement of cellular immunity is central in the pathophysiology of MS. 
MS is predominantly characterized by local T cell and macrophage infiltration and 
autoantibody production, leading to demyelination and loss of neurologic function. 
MS is an autoimmune disease triggered by CD4+ T cells, mainly Th1. More recently, 
Th17 cells have been shown to be involved in MS. Antigens within the myelin 
sheath, such as myelin basic protein, proteolipid protein, and myelin oligodendrocyte 
glycoprotein, have been described as the main targets of self-reactive CD4+ T cells 
and autoantibodies.1–3International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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T regulatory cells (Tregs), especially thymus-derived 
natural Tregs (CD4+CD25+FoxP3+ T cells), are of major 
importance in the maintenance of immune tolerance to self- 
and alloantigens.4 Impairment of the inhibitory function of 
natural Tregs seems to play an important role in MS disease 
pathogenesis.5
MS usually affects young adults aged 20–40 years, 
although it can begin earlier or later in life. Women are 
affected almost twice as often as men. The most common 
symptoms include sensory disturbances in the limbs, optic 
nerve dysfunction, pyramidal tract dysfunction, bladder or 
bowel dysfunction, sexual dysfunction, ataxia, and diplo-
pia. The course of MS can follow four clinical patterns, ie, 
relapsing–remitting MS (RR-MS) accounting for 80%–90% 
of MS cases at onset, secondary progressive MS, primary 
progressive MS, and progressive relapsing MS.1
Results from autologous bone marrow transplantation 
(BMT) or stem cell transplantation6 applied to .400 MS 
patients between 1995 and 2008 showed improvement in 
more than 60% of the patients for at least three years post-
transplantation, with a mortality risk of 2%–10%. The accu-
mulated experience from these trials helped clarify certain 
important points, ie, stem cell transplantation6 works better 
with early aggressive MS, whereas when this treatment is 
applied to patients with progressive MS and long disease 
duration, it has minor or moderate results, and intermediate-
intensity pretransplant conditioning regimens work equally 
as well as toxic high-intensity regimens.7–10
Results from heterologous stem cell transplantation6 are 
very few (about five published cases). In all these cases, stem 
cell transplantation was performed to treat a hematologic 
malignancy with concurrent MS. MS improved in three of 
these patients, whereas in two patients it remained active.11
Natalizumab is a new drug that is being used as mono-
therapy for relapsing forms of severe MS refractory to 
conventional treatments.12 Natalizumab contains humanized 
neutralizing IgG4k monoclonal antibodies to leukocyte 
a4 integrins, which include a4β7 and a4β1, found on lympho-
cytes and monocytes. By blocking a4 integrins, natalizumab 
blocks lymphocyte and monocyte trafficking to the sites of 
inflammation.12
In this work we sought to determine changes in lym-
phocyte subsets in the peripheral blood of an RR-MS 
patient refractory to conventional treatments and BMT who 
responded to natalizumab, with emphasis on the size and 
function of the patient’s Treg population. The patient’s data 
are compared with data obtained from 11 RR-MS patients, 
under no treatment or treated with interferon (IFN)-β, and 
20 healthy controls, in order to get a clear idea of the cell 
populations that can be considered as major players in the 
pathogenesis of this complex disease.
Methods
Patient   A: Case presentation
In 1998, a previously healthy 23-year-old man without a 
family history of neurologic disorders was admitted to our 
  hospital because of numbness and weakness of the right leg 
and urinary urgency and incontinence. Ten days earlier, he 
had experienced the same symptoms in the left leg. One month 
earlier, he had also experienced loss of vision in the right eye 
that resolved rapidly, spontaneously, and completely.
A neurologic examination revealed decreased strength, 
hypopallesthesia, and hyperreflexia in the left leg, absent 
abdominal reflexes, no plantar response bilaterally, and a 
positive Hoffmann’s sign on the right.
Brain and spinal cord magnetic resonance imaging (MRI) 
with contrast showed an 8 mm lesion in the right parietal 
lobe and several lesions in the cervical medulla with demy-
elinating characteristics. Laboratory tests, including blood 
chemistry, and immunologic, rheumatologic, and thyroid 
screening, were normal. Examination of the cerebrospinal 
fluid, including IgG index, was normal. Multimodal evoked 
potentials showed alterations in visual responses.
The patient was given steroid treatment with intravenous 
methylprednisolone 500 mg/day for five days, with tapering, 
and the symptoms gradually subsided.
Two months later, the diagnosis of MS was confirmed on 
the basis of occurrence of a new clinical episode character-
ized by numbness and weakness of the left leg. He began 
receiving 30 µg of IFNβ-1α intramuscularly once weekly.
In the following seven months, the patient experienced 
several clinical recurrences involving the pyramidal, cerebel-
lar, sensory, and oculomotor functional systems, that remit-
ted after high doses of steroids. The therapy was changed to 
IFN-1β, but the recurrences continued about once per one 
or two months for the following year.
In May 2000, the patient underwent elective autologous 
BMT, and for one year he had no new clinical episodes. After one 
year, he started 30 µg of IFNβ-1α intramuscularly once weekly 
as prophylactic treatment. The treatment was changed again to 
IFNβ-1α 44 µg subcutaneously every second day because of 
two new clinical episodes but the recurrences continued.
In May 2003, the patient began treatment with mitoxan-
drone that lasted for two years. During this period, and for 
the following two years, he was free of symptoms and recur-
rences, without receiving any additional treatment.
In March 2007, the patient started having new episodes 
that, from then on, occurred every three months, with International Journal of General Medicine 2010:3
Table 1 Clinical and demographic data for Ms patients and healthy controls
Subjects Gender Age Type of disease Phase of disease Treatment EDSS Disease duration
Ms patients 
(n = 11)
9F/3M 34.83  
(17–66)
RR Acute* None (n = 8) 
IFN-β (n = 4)
2.58 
(1–6.5)
4.22 
(0–19)
Healthy subjects 
(n = 20)
12F/8M 28.5 
(20–52)
na na na na na
Notes: Age (years), duration of disease (years), and eDss scores are given as median (range). *At the time the blood sample was drawn.
Abbreviations: Ms, multiple sclerosis; eDss, expanded Disability status score; n, sample size; F, female; M, male; na, not applicable; IFN-β, interferon-beta (under continuous 
prophylactic therapy with IFN-β1β, Betaferon, schering AG, 0.25 mg subcutaneously every second day; IFN-β1α, Avonex, Biogen Inc., 30 µg intramuscularly once a week; or 
Rebif®, serono AG, 44 µg subcutaneously every second day).
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  difficulty in walking, numbness of the lower extremities, 
urinary urgency and incontinence, and sexual dysfunction. 
He received treatment with high doses of intravenous steroids 
during each clinical episode without complete recovery.
In November 2007, the patient was hospitalized for a new 
clinical evaluation. The Expanded Disability Status Score 
(EDSS) score at this time was 5.5. Brain MRI with contrast 
showed nonenhancing foci with increased signal, characteris-
tic of MS, in both the temporal lobes, the brainstem, the corpus 
callosum, and periventricularly, especially in the left cerebral 
hemisphere, and one enhancing lesion in the left occipital 
lobe. Spinal cord MRI with contrast revealed several enhanc-
ing and nonenhancing lesions from A2 to T1. Immunologic 
testing was normal. It was decided to start treatment with 
natalizumab, which was well tolerated. He has been receiving 
natalizumab for 22 months, with no new clinical episodes and 
a slight improvement in the EDSS score (4.5–5.0).
Controls
Eleven other patients with RR-MS were studied in parallel. 
All were patients at the Neurology Clinic of the Patras 
University Hospital, and did not suffer from any additional 
ailments. A second control group consisted of 20 healthy 
volunteers. Samples of heparinized peripheral blood (3 mL) 
were drawn from patient A at various time points (see Results 
section) and from controls only once. Clinical and laboratory 
parameters of the control subjects are shown in Table 1.
Informed consent was obtained from all participants 
in the study. Patras University Hospital abides by the Hel-
sinki Declaration on ethical principles for medical research 
i  nvolving human subjects.
Methods
Immunophenotyping of peripheral  
blood mononuclear cells
Blood samples drawn from the study subjects were incubated 
with fluorescent-labeled antihuman monoclonal   antibodies 
(mAbs) CD3-FITC, CD4-FITC, CD8-FITC, CD25-PE, 
CD45RA-PE, CD45RO-PE, CD20-FITC, CD5-PE, CD56-PE, 
HLA B7-PE, Vβ3-PE, Vβ5-FITC, Vβ8-FITC, Vβ9-FITC, 
Vβ23-FITC, and FoxP3-PC5. All mAbs were from BD 
  Biosciences/Pharmingen (San Diego, CA); CD4-FITC was 
from Beckman Coulter (Fullerton, CA); CD8-FITC was 
from Daco A/S (Glostrup, Denmark); FoxP3-PC5 was from 
eBioscience (San Diego, CA). All experimental procedures 
were carried out following the manufacturers’ instructions for 
fluorescent activated cell sorting analysis in whole blood. Nega-
tive controls consisted of isotype-matched irrelevant antibodies, 
substituting specific antibodies at equivalent concentrations. 
Flow cytometric acquisition and analysis were performed on 
at least 50,000 acquired events (gated on lymphocytes) per 
sample, using a Coulter EPICS-XL-MCL cytometer. The data 
were analyzed using FlowJo V7.5   software (Tree Star Inc., 
Ashland, OR).
PBMC culture with myelin basic  
protein peptide
Peripheral blood mononuclear cells (PBMC) were isolated 
from patient A or controls by centrifugation over a Ficoll-Paque 
gradient (Pharmacia, Sweden). The cells were cultured O/N in 
RPMI1640 medium (GIBCO BRL, Gaithersburg, MD), con-
taining 10% fetal bovine serum and 1% penicillin/streptomycin 
at a concentration of 106 cells/mL, in the presence or absence 
of peptide cP7 at a concentration 10 pg/mL/106 cells. Peptide 
cP7 (Figure 1) is a modified myelin basic protein antigenic 
epitope that elicits a very strong Th1 response by peripheral 
blood effector T cells of RR-MS patients in the acute phase of 
the disease before treatment or under continuous prophylactic 
therapy with IFN-β.13
Immunophenotyping of cultured cells
At the end of culture, the cells (106 cells/mL in phosphate-
buffered saline) were incubated with the mAbs CD4-FITC 
(Beckman Coulter), and CD25-PE (BD) and FoxP3-PC5 
(eBioscience). All experimental procedures were carried out 
following the manufacturers’ instructions for cultured PBMC. 
Negative controls consisted of isotype-matched irrelevant 
antibodies, substituting specific antibodies at equivalent 
concentrations. Flow cytometric acquisition and analysis 
were performed on at least 50,000 acquired events (gated on International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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lymphocytes) per sample, using a Coulter EPICS-XL-MCL 
cytometer. The data were analyzed using FlowJo V7.5 soft-
ware (Tree Star Inc.).
statistical analysis
The results are presented as mean values (±standard devia-
tion, SD). Comparisons between groups were performed 
using the Student’s t test. The P values were calculated as 
two-tailed, and in all cases were considered statistically sig-
nificant if P was #0.05.
Results
Phenotypic analysis of peripheral  
blood lymphocytes
The results of the phenotypic analysis performed on blood 
samples drawn from the MS and healthy controls are shown 
in Table 2. The differences between MS patients and controls 
that were statistically significant were the percentage of 
CD4+CD25+FoxP3+ T regulatory cells, that were about 64% 
lower in MS patients, HLA-B7 positive cells that were about 
580% higher in MS patients, and the percentage of B cells 
(CD20) that were about 62% higher in MS patients. From the 
T cell receptor repertoire markers studied, Vβ5 was increased 
in MS patients compared with controls by about 30%, but the 
difference did not reach statistical significance.
Phenotypic analysis of peripheral  
blood lymphocytes in patient   A  
before and after natalizumab
Blood samples were drawn from patient A 11 times, spanning 
a period of five months since the beginning of his treatment 
with natalizumab (points S1–S11, shown in   Figures 2–4). The 
samples were invariably drawn once a month,   immediately 
before and 24 hours after treatment administration, with the 
exception of point S3, where a blood sample was also drawn 
on day 15 after the first treatment. During this time period, 
the patient developed flu-like symptoms with fever twice; 
the first time soon after the first natalizumab administration 
(between points S2 and S3), and the second time 20 days 
after the second natalizumab administration (between points 
S5 and S6).
Figures 2–4 show plots of the changes in the percentages 
of patient A’s cell populations with time. Seven years after 
patient A underwent BMT, and immediately before receiving 
natalizumab treatment (point S1), he presented with dimin-
ished naive T helper (CD4+CD45RA+, Figure 3) and natural 
killer (CD3-CD56+, Figure 4) cell populations, whereas the 
rest of the populations studied were within the RR-MS control 
range (Table 1 and Figures 2–4).
Natalizumab treatment in patient A resulted in lym-
phocytosis (Figure 2) and a relative increase in the per-
centages of CD20+ B cells (Figure 2), the CD20+CD5+ 
B cell   subset (  Figure 2), and CD4+CD25+FoxP3+ Tregs 
(Figure 4). The patient maintained relatively low CD3+ T 
cells (Figure 2), CD3+CD4+ T helper cells, CD4+CD45RO+ 
memory T helper cells, and CD8+CD45RA+ cytotoxic T 
PHE 90
CIT 97
CIT 91
HIS 88
PHE 89
Figure 1 Lowest energy conformation of the peptide analog cP7 used in this work. 
cP7: cyclo (87–99) Cit91, Ala96, Cit97 MBP87–99: ValHisPhePheCit91 AsnIleValThrAla96 
CitThrPro.
Table 2 Cell surface immunophenotyping of peripheral blood 
lymphocytes of Ms patients and healthy controls
Cell population (%) Healthy controls  
(n = 20)
RR-MS patients   
(n = 11)
Lymphocytes 34.54 (±5.84) 33.81 (±14.67)
CD3+ 74.7 (±7.4) 72.1 (±8.9)
CD4+ 43.2 (±4.8) 44.4 (±10.8)
CD8+ 26.9 (±5.8) 25.1 (±6.5)
CD4+CD45RA+ 52.3 (±16.4) 45.7 (±9.1)
CD8+CD45RA+ 22.9 (±5.2) 16.4 (±3.5)
CD4+CD45RO+ 28.5 (±7.1) 30.4 (±5.6)
CD8+CD45RO+ 6.2 (±2.2) 8.5 (±4.4)
CD4+CD25+FoxP3+ 1.74 (±0.83) 0.63 (±0.44)*
CD20+ 9.6 (±2.8) 15.6 (±5.1)*
CD20+CD5+ 0.64 (±0.37) 0.8 (±0.44)
CD3-CD56+ 10.54 (±3.62) 9.5 (±3.5)
HLA-B7+ 1.0 (±1.0) 6.8 (±4.7)*
Vβ8+ 79.0 (±4.6) 82.5 (±5.6)
Vβ3+ 84.6 (±5.2) 89.7 (±4.5)
Vβ5+ 64.5 (±3.5) 83.6 (±5.6)
Vβ9+ 73.8 (±5.4) 85.2 (±7.9)
Vβ23+ 70.8 (±6.3) 67.7 (±11.7)
Notes: The results are given as mean (±standard deviation). *P , 0.05, student’s 
t-test.
Abbreviations: Ms, multiple sclerosis; HLA, human leukocyte antigen; RR-Ms, 
relapsing-remitting multiple sclerosis.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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cells (Figure 3), and very low levels of naive CD4+CDRA+ 
T helper cells (Figure 3) and CD3-CD56+ natural killer cells 
(  Figure 4) throughout.
Ability of Tregs to respond to the 
antigenic peptide cP7 in culture
PBMC isolated from patient A and the controls were cultured 
O/N ± peptide cP7. The absolute numbers and percentages 
of CD4+CD25+FoxP3+ Tregs were determined as shown in 
Figure 5A–D. The results of the phenotypic analysis of all 
samples (patient A, MS patients, and healthy controls) are 
shown in Figure 5E. Incubation with the peptide increased the 
percentage of Tregs in control PBMC by an average of 15%, 
whereas it had no effect on or slightly decreased the percent-
age of RR-MS control Tregs by about 3%. In patient A, at 
time point S1 (prenatalizumab treatment) PBMC incubation 
with the peptide resulted in a 21% decrease of Tregs, whereas 
postnatalizumab treatment (from time point S2 onwards) 
PBMC incubation with the peptide increased the percentage 
of Tregs by an average of 42%.
Discussion
The immune system of patient A was being influenced 
by three independent variables, ie, the disease, BMT, 
and treatment with natalizumab. Phenotypic analysis of 
patient A’s lymphocytes, seven years after BMT and before 
receiving natalizumab treatment, showed that most of the 
cell types studied were within or at the low end of the control 
RR-MS range, whereas his naive T helper and natural killer 
cell levels were very low. Muraro et al14 showed that in seven 
patients with different types of MS (one with RR-MS) who 
  underwent autologous hematopoietic stem cell   transplantation 
and did not relapse during a two-year follow-up, there were 
no significant differences from pretherapy in the proportions 
of CD3+ T cells, CD19+/CD20+ B cells, natural killer 
(CD3-CD56+) cells, natural killer T cells (CD3+ CD56+), and 
CD14+ monocytes. The CD4+/CD8+ ratio was significantly 
decreased due to the greater impact of therapy on CD4+ 
T cells during the first months, but reverted towards baseline 
at one year and reached pretherapy levels at two years. They 
also showed a doubling of the frequency of naïve CD4+ T cells 
at the expense of memory T cells.
Natalizumab treatment of patient A resulted in lympho-
cytosis, reflecting the successful antagonism of a4 integrin.12 
Analysis of the lymphocyte populations of patient A revealed 
that lymphocytosis resulted mainly from increased levels of 
his CD20+ and CD20+CD5+ B cells, which may indicate an 
increase in the production of T cell-dependent and natural 
antibodies.15,16 Linberg et al17 examined the gene expression 
profiles in peripheral blood cells of MS patients who had 
been treated with natalizumab for more than two years and 
compared them with placebo-treated patients. They reported 
sustained altered transcription patterns of several genes 
expressed in lymphocytes, neutrophils, or erythrocytes, 
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Figure 2 Plots of the changes in the percentages of patient’s A lymphocytes, T cells (CD3+), B cells (CD20+), and the CD20+CD5+ B cell subset before (time point s1) 
and at several time points spanning five months (S2–S11) postnatalizumab treatment. The samples were invariably drawn once a month, immediately before and 24 hours 
after treatment administration, with the exception of point S3 where a blood sample was also drawn on day 15 after the first treatment. During this time period, the patient 
developed flu-like symptoms with fever twice. The first time soon after the first natalizumab administration (between points S2 and S3), and the second time 20 days after 
the second natalizumab administration (between points s5 and s6). The plots are set against a background of the range of values obtained from the control RR-Ms patients 
(Ms, n = 11) and healthy controls (HC, n = 20).
Abbreviations: HC, healthy controls; Ms, multiple sclerosis; RR-Ms, relapsing-remitting multiple sclerosis.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Figure 3 Plots of the changes in the percentages of patient A’s T helper cells (CD3+CD4+), T helper naive cells (CD4+CD45RA+), T helper memory cells (CD4+CD45RO+), 
T cytotoxic cells (CD3+CD8+), T cytotoxic naive cells (CD8+CD45RA+), and T cytotoxic memory cells (CD8+CD45RO+) before (time point s1) and at several time 
points spanning five months (S2–S11) postnatalizumab treatment. The plots are set against a background of the range of values obtained from the control RR-MS patients   
(Ms, n = 11) and healthy controls (HC, n = 20). For details on s1–s11 time points, compare with legend to Figure 2. 
Abbreviations: HC, healthy controls; Ms, multiple sclerosis; RR-Ms, relapsing-remitting multiple sclerosis.
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Figure 4 Plots of the changes in the percentages of patient A’s natural killer T cells (CD3-CD56+) and CD4+CD25+FoxP3+ T regulatory cells (Tregs) before (time point s1) 
and at several time points spanning five months (S2–S11) postnatalizumab treatment. The plots are set against a background of the range of values obtained from the control 
RR-Ms patients (Ms, n = 11) and healthy controls (HC, n = 20). For details on s1–s11 time points, compare with legend of Figure 2.
in particular those genes involved in B cell activation and 
differentiation.
Patient A’s effector T cell levels remained unchanged 
postnatalizumab treatment, with his naive T helper cells 
and natural killer cells remaining at extremely low levels 
throughout the study period. Decreased levels of CD4+ 
T helper cells during natalizumab treatment have also been 
reported in earlier studies.18,19
Finally, in patient A, natalizumab treatment resulted in a 
stable increase of his natural (CD4+CD25+FoxP3+) Tregs. 
Nevertheless, their numbers remained low compared with 
Tregs of healthy controls, ie, within the RR-MS control range. 
In accordance with previous studies5 that have reported a lack 
of function of Tregs in MS, patient A’s Tregs before   natalizumab 
treatment, when cultured with a strong myelin basic protein 
self-antigen, failed to respond and actually decreased in 
  number, similar to Tregs from the RR-MS controls. In contrast, 
postnatalizumab treatment, patient A’s Tregs responded well to 
the self-antigen, maintaining a stable increase of about 42%, 
ie, patient A acquired functional Tregs.International Journal of General Medicine 2010:3 submit your manuscript | www.dovepress.com
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Taken together, the results suggest that BMT failed to 
generate new T cells, natural killer cells, and Tregs in patient 
A, and this is probably the reason why this patient relapsed.
It has been reported that, in MS patients treated with 
natalizumab, there are increased numbers of circulating 
hematopoietic stem/progenitor cells that are chronically 
maintained.20–22 Although the fate of these circulating 
hematopoietic stem/progenitor cells and their clinical 
relevance for MS patients remain to be determined, it is 
possible that natalizumab treatment results in the generation 
of new lymphocytes and new functional Tregs in the patients 
and also in new myelinogenic or neural cells. These events may 
account for the improved clinical condition of patient A.
To our knowledge, this is the first work that reports improved 
Treg function in an RR-MS patient who received natalizumab 
treatment. According to a recent study,   natalizumab   treatment 
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Figure 5 Flow cytometric analysis to determine CD4+CD25+FoxP3+ T regulatory cell levels in PBMC isolated from patient A and the controls and cultured O/N ± 
peptide cP7. PBMC were stained with CD4, CD25, and, intracellularly, with FoxP3-specific mAbs, then analyzed on a Coulter EPICS-XL-MCL. A) The PBMC were gated 
on lymphocytes (based on forward and side light scatter) and B) analyzed for CD4 and CD25 expression. C) The double positive cells (Q2) were analyzed further for 
FoxP3 expression. The numbers in the A, B, C plots indicate the percentage of gated cells expressing the relevant marker. D) shows the absolute number of cells per each 
population analyzed in A, B, and C. The results of the analysis of all samples (patient A, Ms patients, n = 11, and HC, n = 20) are shown in E) Left-hand panel shows the 
percentage of CD4+CD25+FoxP3+ Tregs after O/N culture of PBMC in plain culture medium; right-hand panel shows changes in the percentage of CD4+CD25+FoxP3+ 
T cells after O/N culture with peptide cP7. Pretreatment, prenatalizumab treatment (point s1); post-treatment, postnatalizumab treatment (points s2–s11). 
Abbreviations: HC, healthy controls; Ms, multiple sclerosis; mAbs, monoclonal antibodies; PBMC, peripheral blood mononuclear cells.International Journal of General Medicine
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of 28 RR-MS patients resulted in a relative decrease in 
natural Tregs, and their impaired suppressive capacity was 
not restored.23 Although a direct comparison cannot be made 
between patient A, who has a history of BMT, and typical 
RR-MS patients who are refractory to conventional treatments 
and are put on natalizumab, a possible explanation is that the 
peptide we used for the Treg functional assays is a citrullinated 
myelin basic protein peptide. It is becoming increasingly appar-
ent that citrullination of self-antigens is a major mechanism in 
triggering autoimmune/inflammatory diseases such as MS.6,13,24 
Future work with RR-MS patients treated with natalizumab, 
in comparison to other types of treatment, will clarify whether 
natalizumab treatment results in the generation of functional 
Tregs in RR-MS patients in general.
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